Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1179

—

dca18007-0b76-5711-bfac-71c3b75f706e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.717
  • G2M_CHECKPOINT+0.666
  • MYC_TARGETS_V1+0.497
  • MTORC1_SIGNALING+0.444
  • MITOTIC_SPINDLE+0.422
  • PROTEIN_SECRETION+0.422
  • ANGIOGENESIS+0.305
  • DNA_REPAIR+0.282
  • NOTCH_SIGNALING+0.273
  • OXIDATIVE_PHOSPHORYLATION+0.257

Top 10 suppressed

  • INTERFERON_GAMMA_RESPONSE-0.349
  • INTERFERON_ALPHA_RESPONSE-0.348
  • KRAS_SIGNALING_DN-0.322
  • TNFA_SIGNALING_VIA_NFKB-0.307
  • MYOGENESIS-0.249
  • ALLOGRAFT_REJECTION-0.248
  • HEDGEHOG_SIGNALING-0.222
  • IL6_JAK_STAT3_SIGNALING-0.165
  • P53_PATHWAY-0.161
  • INFLAMMATORY_RESPONSE-0.159

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG409
mng-umap@100
——0.877
2MNG169
mng-umap@100
——0.865
3MNG1011
mng-umap@100
——0.864
4R265
bladder-landscape@3
——0.862
5TCGA-22-5483-01A-01R-1820-07
lung-landscapes@6
—cohortMD10.860
6TCGA-AN-A0G0-01A-11R-A034-07
breast-umap@18
—E0.858
7MNG257
mng-umap@100
——0.854
8MNG753
mng-umap@100
——0.850
9TCGA-BT-A20N-01A-11R-A14Y-07
bladder-landscape@3
——0.848
10ERR2598169
medullo-epn-umap@date-based
fetalfetal0.838

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.717Inavolisib— uncovered
G2M_CHECKPOINT0.666Inavolisib— uncovered
MYC_TARGETS_V10.497Inavolisib— uncovered
MTORC1_SIGNALING0.444Inavolisib— uncovered
MITOTIC_SPINDLE0.422Inavolisib— uncovered
PROTEIN_SECRETION0.422Remibrutinib— uncovered
ANGIOGENESIS0.305Remibrutinib— uncovered
DNA_REPAIR0.282Idelalisib— uncovered
NOTCH_SIGNALING0.273Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.257Remibrutinib— uncovered
ANDROGEN_RESPONSE0.213Inavolisib— uncovered
GLYCOLYSIS0.209Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.206Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.189Idelalisib— uncovered
MYC_TARGETS_V20.182Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.149Remibrutinib— uncovered
ADIPOGENESIS0.126Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.123Inavolisib— uncovered
UV_RESPONSE_DN0.120Inavolisib— uncovered
FATTY_ACID_METABOLISM0.115Inavolisib— uncovered